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Abstract
As the development of a dengue vaccine is ongoing, we simulate an hypothetical vaccine as an
extra protection to the population. In a first phase, the vaccination process is studied as a new
compartment in the model, and different ways of distributing the vaccines investigated: pediatric
and random mass vaccines, with distinct levels of efficacy and durability. In a second step, the
vaccination is seen as a control variable in the epidemiological process. In both cases, epidemic
and endemic scenarios are included in order to analyze distinct outbreak realities.
Keywords: dengue; vaccine; SVIR model; optimal control.
2010 Mathematics Subject Classification: 92B05, 65L05, 49J15.
1. Introduction
Since 1760, when the Swiss mathematician Daniel Bernoulli published a study on the impact of
immunization with cowpox, the process of protecting individuals from infection by immunization
has become a routine, with historical success in reducing both mortality and morbidity [1]. The
impact of vaccination may be regarded not only as an individual protective measure, but also
as a collective one. While direct individual protection is the major focus of a mass vaccination
program, the effects on population also contribute indirectly to other individual protection through
herd immunity, providing protection for unprotected individuals [2]. This means that when we
have a large neighborhood of vaccinated people, a susceptible individual has a lower probability in
coming into contact with the infection, being more difficult for diseases to spread, which decreases
the relief of health facilities and can break the chain of infection.
Dengue is a vector-borne disease that transcends international borders. It is transmitted to
humans through mosquito bite, mainly the Aedes aegypti. In this process the female mosquito
acquires the virus while feeding on the blood of an infected person. The blood is necessary to
feed their eggs. Larvae hatch when water inundates the eggs as a result of rains or an addition of
water by people. When the larva has acquired enough energy and size, metamorphosis is done,
changing the larva into pupa. The newly formed adult emerges from the water after breaking the
pupal skin. This process could lasts between 8 to 10 days [3]. Vector control remains the only
available strategy against dengue. Despite integrated vector control with community participation,
along with active disease surveillance and insecticides, there are only a few examples of successful
dengue prevention and control on a national scale [4]. Besides, the levels of resistance of Aedes
aegypti to insecticides has increased, which implies shorter intervals between treatments, and only
few insecticide products are available in the market due to the high costs for development and
registration and low returns [5].
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Dengue vaccines have been under development since the 1940s, but due to the limited appre-
ciation of global disease burden and the potential markets for dengue vaccines, industry interest
languished throughout the 20th century. However, in recent years, the development of dengue vac-
cines has dramatically accelerated with the increase in dengue infections, as well as the prevalence
of all four circulating serotypes. Faster development of a vaccine became a serious concern [6].
Economic analysis are conducted to guide public support for vaccine development in both indus-
trialized and developing countries, including a previous cost-effectiveness study of dengue [7, 8, 9].
The authors of these works compared the cost of the disease burden with the possibility of making
a vaccination campaign; they suggest that there is a potential economic benefit associated with
promising dengue interventions, such as dengue vaccines and vector control innovations, when
compared to the cost associated to the disease treatments. Constructing a successful vaccine for
dengue has been challenging: the knowledge of disease pathogenesis is insufficient and in addition
the vaccine must protect simultaneously against all serotypes in order to not increase the level of
dengue haemorrhagic fever [10].
Currently, the features of a dengue vaccine are mostly unknown. Therefore, in this paper
we opt to present a set of simulations with different efficacy and different ways of distributing
the vaccine. We have also explored the vaccination process under two different perspectives. In
Section 2 a new compartment in the model is used and several kinds of vaccines are considered. In
Section 3, a second perspective is studied using the vaccination process as a disease control in the
mathematical formulation. In that case the theory of optimal control is applied. Both methods
assume a continuous vaccination strategy.
2. Vaccine as a new compartment in the model
The interaction human-mosquito is detailed in a previous work by the authors [11]. See also
[12]. The notation used in our mathematical model includes four epidemiological states for humans:
Sh(t) — susceptible (individuals who can contract the disease);
Vh(t) — vaccinated (individuals who were vaccinated and are now immune);
Ih(t) — infected (individuals who are capable of transmitting the disease);
Rh(t) — resistant (individuals who have acquired immunity).
It is assumed that the total human population (Nh) is constant, so, Nh = Sh + Vh + Ih + Rh.
The compartment Vh represents the group of human population that is vaccinated, in order to
distinguish the resistance obtained through vaccination and the one achieved by disease recovery.
There are also three other state variables, related to the mosquitoes:
Am(t) — aquatic phase (includes the eggs, larva and pupa stages);
Sm(t) — susceptible (mosquitoes able to contract the disease);
Im(t) — infected (mosquitoes capable of transmitting the disease to humans).
Similarly to the human population, it is assumed that the total adult mosquito population is
constant, which means Nm = Sm + Im. There is no resistant phase in mosquitoes due to its
short lifespan and the fact that the coefficient of disease transmission is considered fixed. Another
assumption is the susceptibility of the humans and mosquitoes when they born. The parameters
of the model are:
Nh — total population;
B — average number of bites on humans by mosquitoes, per day;
βmh — transmission probability from Im (per bite);
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βhm — transmission probability from Ih (per bite);
1/µh — average lifespan of humans (in days);
1/ηh — mean viremic period (in days);
1/µm — average lifespan of adult mosquitoes (in days);
ϕ — number of eggs at each deposit per capita (per day);
1/µA — natural mortality of larvae (per day);
ηA — maturation rate from larvae to adult (per day);
m — female mosquitoes per human;
k — number of larvae per human.
Two forms of random vaccination are possible. The most common to reduce the prevalence of an
endemic disease is pediatric vaccination; the alternative being random vaccination of the entire
population in an outbreak. In both cases, the vaccination can be considered perfect, conferring
100% protection along all life, or imperfect. This last case can be due to the difficulty of producing
an effective vaccine, the heterogeneity of the population or even the life span of the vaccine.
2.1. Perfect pediatric vaccine
For many potentially human infections, such as measles, mumps, rubella, whooping cough,
polio, there has been much focus on vaccinating newborns or very young infants. Dengue can be
a serious candidate for this type of vaccination. In the SV IR model, a continuous vaccination
strategy is considered, where a proportion of the newborn p (where 0 ≤ p ≤ 1), was by default
vaccinated. This model also assumes that the permanent immunity acquired through vaccination
is the same as the natural immunity obtained from infected individuals eliminating the disease
naturally. The population remains constant, i.e., Nh = Sh+Vh+Ih+Rh. The model is represented
in Figure 1. The mathematical formulation is:
Figure 1: Epidemic model using a pediatric vaccine.
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
dSh
dt (t) = (1− p)µhNh −
(
Bβmh
Im(t)
Nh
+ µh
)
Sh(t)
dVh
dt (t) = pµhNh − µhVh(t)
dIh
dt (t) = Bβmh
Im(t)
Nh
Sh(t)− (ηh + µh)Ih(t)
dRh
dt (t) = ηhIh(t)− µhRh(t)
dAm
dt (t) = ϕ
(
1− Am(t)kNh
)
(Sm(t) + Im(t))− (ηA + µA)Am(t)
dSm
dt (t) = ηAAm(t)−
(
Bβhm
Ih(t)
Nh
+ µm
)
Sm(t)
dIm
dt (t) = Bβhm
Ih(t)
Nh
Sm(t)− µmIm(t).
(1)
We are assuming that the vaccine is perfect, which means that it confers life-long protection. The
nontrivial disease-free equilibrium for system (1) is given by
Sh = (1− p)Nh, Vh = pNh, Ih = 0, Rh = 0,
Am =
(
1− ηA + µA
ϕηA
µm
)
kNh, Sm =
ηA
µm
Am, Im = 0.
As a first step, we determine the basic reproduction number without vaccination (p = 0).
Theorem 2.1. Without vaccination, the basic reproduction number R0, associated to the differ-
ential system (1), is given by
R0 =
√
kB2βhmβmh (−ηAµm − µAµm + ϕηA)
ϕ(ηh + µh)µ2m
. (2)
Proof. The proof is similar to the one presented in [13].
We do all the simulations in two scenarios: an epidemic and an endemic situation. The
following values for the parameters of the differential system and initial conditions were used
(Tables 1 and 2). These values are based on previous works [11, 13]. A small number of initial
infected individuals (Ih0 = 10) is considered, to simulate an early action by the health authorities.
We recall that dengue is endemic when it occurs several times in a year, and is not related with
the initial value of infected individuals. Moreover, a small initial value of infected individuals in
an endemic scenario is in agreement with [14]. In our work the same initial value of Ih for both
epidemic and endemic scenarios is important in order to compare the development of the disease.
Parameter Epidemic scenario Endemic scenario
Nh 480000 480000
B 0.8 0.75
βmh 0.375 0.21
βhm 0.375 0.21
µh
1
71×365
1
71×365
ηh
1
3
1
3
µm
1
10
1
10
ϕ 6 6
µA
1
4
1
4
ηA 0.08 0.08
m 3 3
k 3 3
Table 1: Parameters values of the differential system (1).
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Initial conditions Epidemic scenario Endemic scenario
Sh0 479990 379990
Vh0 0 0
Ih0 10 10
Rh0 0 100000
Am0 1440000 1440000
Sm0 1440000 1440000
Im0 0 0
Table 2: Initial conditions of the differential system (1).
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(a) Epidemic scenario
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(b) Endemic scenario
Figure 2: Human population in a dengue outbreak, without vaccine.
Two main differences between an epidemic episode and an endemic situation were found.
Firstly, in the endemic situation there was a slight decrease in the average daily biting B and
transmission probabilities βmh and βhm, which can be explained by the fact that the mosquito
may have more difficulties to find a naive individual. The second difference is concerned with
the strong increase of the initial human population that is resistant to the disease. This can
be explained by the fact that the disease, in an endemic situation, already creates an immune
resistance to the infection, i.e., the population already has herd immunity. With our values we
obtain approximately R0 = 2.46 and R0 = 1.29 for epidemic and endemic scenarios, respectively.
During an outbreak, the disease transmission assumes different behaviors, according to the
distinct scenarios, as can been seen in Figure 2. In one year, the peak in an epidemic situation
could reach more than 80000 cases. In contrast, in the endemic situation the curve of infected
individuals has a more smooth behavior and reaches a peak less than 3000 cases. Figure 3 relates
to the mosquito population. In the endemic scenario, because a substantial part of the human
population is resistant to the disease, the infected mosquitoes bite a considerable percentage of
resistant host and, as consequence, the disease is not transmitted.
Suppose that at time t = 0 a proportion p of newborns is vaccinated with a perfect vaccine
without side effects. Since this proportion, p, is now immune, R0 is reduced, creating a new basic
reproduction number Rp0.
Definition 1 (cf. [1]). The basic reproduction number with pediatric vaccination, Rp0, associated
to the differential system (1), is given by Rp0 = (1− p)R0, where R0 is defined by (2).
Observe thatRp0 ≤ R0. Equality is only achieved when p = 0, i.e., when there is no vaccination.
Note that the constraint Rp0 < 1 defines implicitly a critical vaccination portion p > pc := 1− 1R0
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(b) Endemic scenario
Figure 3: Mosquito population in a dengue outbreak, without vaccine.
that must be achieved for eradication. Since vaccination entails costs, to choose the smallest
coverage that achieves eradication is the best option. This way, the entire population does not
need to be vaccinated in order to eradicate the disease (this is the herd immunity phenomenon).
Vaccinating at the critical level pc does not instantly lead to disease eradication. The immunity
level within the population requires time to build up and at the critical level it may take a few
generations before the required herd immunity is achieved. Thus, from a public health perspective,
pc acts as a lower bound on what should be achieved, with higher levels of vaccination leading
to a more rapid elimination of the disease. Figure 4 shows simulations with different proportions
of the newborns vaccinated, in both epidemic and endemic scenarios. Note that at time t = 0
no person was vaccinated. In the epidemic situation, as the outbreak reaches a peak at the
beginning of the year, the proportion of newborns vaccinated at that time is minimum and cannot
influence the curve of infected individuals, giving the optical illusion of a single curve. On the
other hand, in the endemic case, as the outbreak occurs later, the vaccination campaign starts
to produce effects, decreasing the total number of sick humans. This last graphic illustrates that
a vaccination campaign centered in newborns is a bet for the future of a country, but does not
produce instantly results to fight the disease. To achieve immediate results, it is necessary to use
random mass vaccination, which means that it is necessary to vaccine a significant part of the
population.
2.2. Perfect random mass vaccination
A mass vaccination program may be initiated whenever there is an increase of the risk of
an epidemic. In such situations, there is a competition between the exponential increase of the
epidemic and the logistical constraints upon mass vaccination. For most human diseases it is
possible, and more efficient, to not vaccinate those individuals who have recovered from the disease,
because they are already protected. Another situation could be the introduction of a new vaccine
in a population that lives an endemic situation. Let us consider the control technique of constant
vaccination of susceptibles. In this scheme a fraction 0 ≤ ψ ≤ 1 of the entire susceptible population,
not just newborns, is being continuously vaccinated. It is assumed that the permanent immunity
acquired by vaccination is the same as natural immunity obtained from infected individuals in
recovery. The epidemiological scheme is presented in Figure 5. The mosquito population remains
equal to the previous subsection, while the mathematical formulation for human population in the
6
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Figure 4: Infected human in an outbreak, varying the proportion of newborns vaccinated (p =
0, 0.25, 0.50, 0.75, 1).
Figure 5: Epidemic model for human population using a mass random vaccine.
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new epidemiological scheme is given by
dSh
dt (t) = µhNh −
(
Bβmh
Im(t)
Nh
+ ψ + µh
)
Sh(t)
dVh
dt (t) = ψSh(t)− µhVh(t)
dIh
dt (t) = Bβmh
Im(t)
Nh
Sh(t)− (ηh + µh)Ih(t)
dRh
dt (t) = ηhIh(t)− µhRh(t).
(3)
For this model, we define a new basic reproduction number Rψ0 .
Definition 2 (cf. [15]). The basic reproduction number with random mass vaccination, Rψ0 ,
associated to the differential system (3), is given by
Rψ0 = R0
(
µh
µh + ψ
)
, (4)
where R0 is defined by (2).
Comparing this model with the model of constant vaccination of newborns, it is apparent that
instead of constantly vaccinating a portion of newborns, a part of the entire susceptible population
is now being continuously vaccinated. Since the natural birth rate µh is usually small, the fraction
pµh of newborns being continuously vaccinated will be also small, whereas in this model, a larger
group ψSh of susceptible can be continuously vaccinated. For this reason, we expect this model
to require a smaller proportion ψ to achieve eradication. Note that Rψ0 ≤ R0. Equality is only
achieved in the limit, when ψ = 0, that is, when there is no vaccination. The constraint Rψ0 < 1
defines implicitly a critical vaccination portion ψ > ψc that must be achieved for eradication:
ψc = (R0 − 1)µh.
Figure 6 illustrates the variation of the number of infected people when a mass vaccination is
introduced. The graphs present five simulations using different proportions of the susceptible
being vaccinated: ψ = 0.05, 0.10, 0.25, 0.50, 1. Observe that, in spite of the calculations being
done in the period of 365 days, the figures only show suitable windows, in order to provide a
better analysis. In both epidemic and endemic scenarios, even with a small coverage of the
population, vaccination dramatically decreases the number of infected. In the epidemic scenario,
the situation has changed from around 80000 cases (with no vaccination, Figure 2) to less than
1200 cases, vaccinating only 5% of the susceptible. In the endemic scenario, the decrease is even
more accentuated.
Until here, we have considered a perfect vaccine, which means that every vaccinated individual
remains resistant to the disease. However, a majority of the available vaccines for the human
population does not produce 100% success in the disease battle. Usually, the vaccines are imperfect,
which means that a minor percentage of cases, in spite of vaccination, are infected.
2.3. Imperfect random mass vaccination
Most of the theory about disease evolution is based on the assumption that the host population
is homogeneous. Individual hosts, however, may differ and they may constitute very different
habitats. In particular, some habitats may provide more resources or be more vulnerable to virus
exploitation [16]. The use of models with imperfect vaccines can describe better this type of
human heterogeneity. Another explanation for the use of imperfect vaccines is that until now
we had considered models assuming that as soon as individuals begin the vaccination process,
they become immediately immune to the disease. However, the time it takes for individuals to
obtain immunity by completing a vaccination process cannot be ignored, because meanwhile an
individual can be infected. In this section a continuous vaccination strategy is considered, where a
fraction ψ of the susceptible class was vaccinated. The vaccination may reduce but not completely
eliminate susceptibility to infection. For this reason, we consider a factor σ as the infection rate of
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Figure 6: Infected human in an outbreak, varying the proportion of susceptible population vacci-
nated (ψ = 0.05, 0.10, 0.25, 0.50, 1).
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vaccinated members. When σ = 0, the vaccine is perfectly effective, when σ = 1, the vaccine has
no effect at all. The value 1 − σ can be understood as the efficacy level of the vaccine. The new
model for the human population is represented in Figure 7. Accordingly, we have the following
Figure 7: Epidemiological SV IR model for human population with an imperfect vaccine.
system of differential equations:
dSh
dt = µhNh −
(
Bβmh
Im
Nh
+ ψ + µh
)
Sh
dVh
dt = ψSh −
(
σBβmh
Im
Nh
+ µh
)
Vh
dIh
dt = Bβmh
Im
Nh
(Sh + σVh)− (ηh + µh)Ih
dRh
dt = ηhIh − µhRh.
(5)
As expected, a new basic reproduction number is associated to (5).
Definition 3 (cf. [17]). The basic reproduction number with an imperfect vaccine, Rσ0 , associated
to the differential system (5), is defined by
Rσ0 = (1 + σψ)
µh
µh + ψ
R0 = (1 + σψ)Rψ0 ,
where Rψ0 is given by (4).
Note that Rψ0 ≤ Rσ0 and when the vaccine is perfect, i.e., σ = 0, Rσ0 degenerates into Rψ0 .
In other words, a high efficacy vaccine leads to a lower vaccination coverage to eradicate the
disease. However, it is realized in [17] that it is much more difficult to increase the efficacy level
of the vaccine when compared to controlling the vaccination rate ψ. Figures 8 and 9 show several
simulations, by varying the vaccine efficacy and the percentage of population that is vaccinated.
Comparing with Figure 6a, in the epidemic scenario with a perfect vaccine, the number of human
infected has reached to a maximum peak of 1200 cases per day, in the worst scenario (ψ = 0.05).
Using an imperfect vaccine, with a level of efficacy of 80% (Figure 8a), with the same values for ψ,
the maximum peak increases until 9000 cases. We conclude that the production of a vaccine with a
high level of efficacy has a preponderant role in the reduction of the disease spread. Figures 9a and
9b reinforce the previous sentence. Assuming that 85% of the population is vaccinated, the number
of infected cases decreases sharply with the increasing of the effectiveness level of the vaccine.
According to [18], an acceptable level of efficacy is at least 80% against all four serotypes, and 3
to 5 for the length of protection. These values are commonly considered, across countries, as the
minimum acceptable levels.
Next we study another type of imperfect vaccine: one that confers a limited life-long protection.
2.4. Random mass vaccination with waning immunity
Until the 1990s, the universal assumption of mathematical models of vaccination was: there is
no waning of vaccine-induced immunity. This assumption was routinely made because, for most
of the major vaccines against childhood infectious diseases, it is approximately correct [1].
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Figure 8: Infected humans in an outbreak varying the proportion of susceptible population vacci-
nated (ψ = 0.05, 0.10, 0.25, 0.50, 1) with a vaccine simulating 80% of effectiveness (σ = 0.2)
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Figure 9: Infected humans in an outbreak varying the efficacy level of the vaccine (σ =
0, 0.10, 0.20, 0.50, 0.75) and considering that 85% of the human susceptible population is vacci-
nated (ψ = 0.85).
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Suppose that the immunity, obtained by the vaccination process, is temporary. Assume that
immunity has the waning rate θ. Then the model for humans is given by
dSh
dt (t) = µhNh + θVh(t)−
(
Bβmh
Im(t)
Nh
+ ψ + µh
)
Sh(t)
dVh
dt (t) = ψSh(t)− (θ + µh)Vh(t)
dIh
dt (t) = Bβmh
Im(t)
Nh
Sh(t)− (ηh + µh)Ih(t)
dRh
dt (t) = ηhIh(t)− µhRh(t).
(6)
This model can be represented by the epidemiological scheme of Figure 10. This leads naturally
Figure 10: Epidemiological SV IR model for human population with a waning immunity vaccine.
to the following basic reproduction number.
Definition 4. The basic reproduction number with an imperfect vaccine, Rθ0, associated to the
differential system (6), is defined by Rθ0 = Rψ0 , where Rψ0 is given by (4).
According to [19], the basic reproduction numbers Rθ0 and Rψ0 are the same, because the
disease will still spread at the same rate with or without temporary immunity. However, we
should expect that the convergence rate will be different between the random mass vaccination
and random mass vaccination with waning immunity, since the disease will be eradicated faster
in the constant treatment model without waning immunity compared to the other with waning
immunity. Figure 11 illustrates this statement. Considering that 85% of human population is
vaccinated, the number of infected is increasing as the value of the waning immunity is growing
(θ = 0, 0.05, 0.10, 0.15, 0.20).
Depending on the vaccine that will be available on the market, it will be possible to choose or
even combine features. In the next section we define the vaccination process as a control system.
3. Vaccine as a control
In this section we consider a SIR model for humans and an ASI model for mosquitoes. The
parameters remain the same as in the previous section. The vaccination is seen as a control variable
to reduce or even eradicate the disease. Let u be the control variable: 0 ≤ u(t) ≤ 1 denotes the
percentage of susceptible individuals that one decides to vaccinate at time t. A random mass
vaccination with waning immunity is selected. In this way, a parameter θ associated to the control
u represents the waning immunity process. Figure 12 shows the epidemiological scheme for the
human population. Note that Rh includes both vaccinated and naturally-immune individuals;
only vaccinated immune individuals have waning immunity. The model is described by an initial
13
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Figure 11: Infected humans in an outbreak considering 85% of susceptible population vaccinated
(ψ = 0.85) and varying waning immunity (θ = 0, 0.05, 0.10, 0.15, 0.20).
Figure 12: Epidemiological SIR model for the human population using the vaccine as a control.
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value problem with a system of six differential equations:
dSh
dt = µhNh −
(
Bβmh
Im
Nh
+ µh + u
)
Sh + θuRh
dIh
dt = Bβmh
Im
Nh
Sh − (ηh + µh)Ih
dRh
dt = ηhIh + uSh − (θu+ µh)Rh
dAm
dt = ϕ
(
1− AmkNh
)
(Sm + Im)− (ηA + µA)Am
dSm
dt = ηAAm −
(
Bβhm
Ih
Nh
+ µm
)
Sm
dIm
dt = Bβhm
Ih
Nh
Sm − µmIm.
(7)
The main aim is to study the optimal vaccination strategy, considering both the costs of treatment
of infected individuals and the costs of vaccination. The objective is to
minimize J [u] =
∫ tf
0
[
γDIh(t)
2 + γV u(t)
2
]
dt, (8)
where γD and γV are positive constants representing the weights of the costs of treatment of
infected people and vaccination, respectively. We solve the problem using optimal control theory.
3.1. Pontryagin’s Maximum Principle
Let us consider the following set of admissible control functions:
∆ = {u(·) ∈ L∞(0, tf ) | 0 ≤ u(t) ≤ 1,∀t ∈ [0, tf ]}.
Theorem 3.1. The problem (7)–(8) with initial conditions (see Table 2), admits a unique optimal
solution (S∗h(·), I∗h(·), R∗h(·), A∗m(·), S∗m(·), I∗m(·)) associated with an optimal control u∗(·) on [0, tf ],
with a fixed final time tf . Moreover, there exists adjoint functions λ
∗
i (·), i = 1, . . . , 6, satisfying
λ˙∗1(t) = (λ1 − λ2)
(
Bβmh
Im(t)
Nh
)
+ λ1µh + (λ1 − λ3)u(t)
λ˙∗2(t) = −2γDIh(t) + λ2(ηh + µh)− λ3ηh + (λ5 − λ6)
(
Bβhm
Sm(t)
Nh
)
λ˙∗3(t) = −λ1θu(t) + λ3(µh + θu(t))
λ˙∗4(t) = λ4ϕ
Sm(t)+Im(t)
kNh
+ λ4(ηA + µA)− λ5ηA
λ˙∗5(t) = −λ4ϕ
(
1− Am(t)kNh
)
+ (λ5 − λ6)Bβhm Ih(t)Nh + λ5µm
λ˙∗6(t) = (λ1 − λ2)
(
Bβmh
Sh(t)
Nh
)
− λ4ϕ
(
1− Am(t)kNh
)
+ λ6µm
(9)
and the transversality conditions λ∗i (tf ) = 0, i=1, . . . 6. Furthermore,
u∗(t) = min
{
1,max
{
0,
(λ1(t)− λ3(t)) (Sh(t)− θRh(t))
2γV
}}
. (10)
Proof. The existence of optimal solutions (S∗h(·), I∗h(·), R∗h(·), A∗m(·), S∗m(·), I∗m(·)) associated to the
optimal control u∗(·) comes from the convexity of the integrand of the cost functional (8) with re-
spect to the control u and the Lipschitz property of the state system with respect to state variables
(Sh, Ih, Rh, Am, Sm, Im) (for more details, see [20, 21]). According to the Pontryagin maximum
principle [22], if u∗(·) ∈ ∆ is optimal for the problem considered, then there exists a nontrivial
absolutely continuous mapping λ : [0, tf ]→ R, λ(t) = (λ1(t), λ2(t), λ3(t), λ4(t), λ5(t), λ6(t)), called
the adjoint vector, such that
S˙h =
∂H
∂λ1
, I˙h =
∂H
∂λ2
, R˙h =
∂H
∂λ3
, A˙m =
∂H
∂λ4
, S˙m =
∂H
∂λ5
, I˙m =
∂H
∂λ6
(11)
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Method Epidemic scenario Endemic scenario
Direct (DOTcvp) 0.07505791 0.00189056
Indirect (backward-forward) 0.06070556 0.00080618
Table 3: Optimal values of the cost functional (8).
and
λ˙1 = − ∂H
∂Sh
, λ˙2 = −∂H
∂Ih
, λ˙3 = − ∂H
∂Rh
, λ˙4 = − ∂H
∂Am
, λ˙5 = − ∂H
∂Sm
, λ˙6 = − ∂H
∂Im
, (12)
where the Hamiltonian H is defined by
H(Sh, Ih, Rh,Am, Sm, Im, λ, u) = γDI
2
h + γV u
2 + λ1
(
µhNh −
(
Bβmh
Im
Nh
+ µh + u
)
Sh + θuRh
)
+ λ2
(
Bβmh
Im
Nh
Sh − (ηh + µh)Ih
)
+ λ3 (ηhIh + uSh − (θu+ µh)Rh)
+ λ4
(
ϕ
(
1− Am
kNh
)
(Sm + Im)− (ηA + µA)Am
)
+ λ5
(
ηAAm −
(
Bβhm
Ih
Nh
+ µm
)
Sm
)
+ λ6
(
Bβhm
Ih
Nh
Sm − µmIm
)
,
together with the minimality condition
H (S∗h(t), I
∗
h(t), R
∗
h(t), A
∗
m(t), S
∗
m(t), I
∗
m(t), λ
∗(t), u∗(t))
= min
u
H (S∗h(t), I
∗
h(t), R
∗
h(t), A
∗
m(t), S
∗
m(t), I
∗
m(t), λ
∗(t), u) , (13)
satisfied almost everywhere on [0, tf ]. Moreover, the transversality conditions λi(tf ) = 0 hold, i =
1, . . . 6. System (9) is derived from (12), and the optimal control (10) comes from the minimality
condition (13).
3.2. Numerical simulations and discussion
The simulations were carried out using the values of Section 2. The values chosen for the weights
in the objective functional (8) were γD = 0.5 and γV = 0.5. The system was normalized, putting
all variables varying from 0 to 1. It was considered that the waning immunity was at a rate of
θ = 0.05. The optimal control problem was solved using two methods: direct [23, 24] and indirect
[25]. The direct method uses the cost functional (8) and the state system (7) and was solved by
DOTcvp [26]. The indirect method used is an iterative method with a Runge–Kutta scheme, solved
through ode45 of MatLab. Figure 13 shows the optimal control obtained by both methods. Note
that DOTcvp only gives the optimal control as a constant piecewise function. Table 3 shows the
costs obtained by the two methods in both scenarios. The indirect method gives a lower cost.
This method uses more mathematical theory about the problem, such as the adjoint system (11)
and optimal control expression (10). Therefore, it makes sense that the indirect method produces
a better result.
Using the optimal solution as reference, some tests were performed, regarding infected indi-
viduals and costs, when no control (u ≡ 0) or upper control (u ≡ 1) is applied. Table 4 shows
the results for DOTcvp in the three situations. In both scenarios, using the optimal strategy of
vaccination produces better costs with the disease, when compared to not doing anything. Once
there is no control, the number of infected humans is higher and produces a more expensive cost
functional. Figure 14 shows the number of infected humans when different controls are considered.
It is possible to see that using the upper control, which means that everyone is vaccinated, implies
that just a few individuals were infected, allowing eradication of the disease. Although the optimal
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Figure 13: Optimal control obtained from direct and indirect approaches, in both epidemic and
endemic scenarios.
Epidemic scenario Endemic scenario
optimal control 0.07505791 0.00189056
no control 0.32326592 0.01045990
upper control 147.82500296 116.800000275
Table 4: Values of the cost functional with optimal control, no control (u ≡ 0), and upper control
(u ≡ 1).
control, in the sense of objective (8), allows the occurrence of an outbreak, the number of infected
individuals is much lower when compared with a situation where no one is vaccinated.
We conclude that, assuming a considerable efficacy level of the vaccine, a vaccination campaign
in the susceptible population can quickly decrease the number of infected people. Figures 15 and
16 show what happens to the optimal solution, in the epidemic and endemic scenarios, respectively,
when the efficacy is changed. These figures confirm an increasing of infected human and control
application with an increasing of the waning immunity rate θ.
4. Conclusions
The worldwide expansion of dengue fever is a growing health problem. In Portugal, on October
2012, for the first time in its history, an outbreak of dengue on the Madeira island occurred. Besides
Aedes albipictus, the other vector that transmits the disease is already in the Old Continent, namely
in Italy and Spain. Dengue vaccine is an urgent challenge that needs to be overcome. This may
be commercially available within a few years, when the researchers will find a formula that protect
against all four dengue viruses. A vaccination program is seen as an important measure used in
infectious disease control and immunization and eradication programs.
In the first part of the paper, different ways of distributing the vaccine, as well as their features
and some of coverage thresholds, were introduced, in order to cover most of the future vaccine
features. The main goal of a vaccination program is to reduce the prevalence of an infectious
disease and ultimately to eradicate it. It was shown that eradication success depends on the type
of vaccine as well as on the vaccination coverage. The imperfect vaccines may not completely
prevent infection but could reduce the probability of being infected, thereby reducing the disease
burden. In this study all the simulations were done using epidemic and endemic scenarios to
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Figure 14: Infected humans when using the optimal vaccination strategy, in terms of (8), no
vaccination (u ≡ 0), and vaccination of all susceptible population (u ≡ 1).
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Figure 15: Optimal solutions for different vaccine efficacies (epidemic scenario).
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Figure 16: Optimal solutions for different vaccine efficacies (endemic scenario).
illustrate distinct realities. A second analysis was made, using an optimal control approach. The
vaccine behaved as a new disease control variable and, when available, can be a promising strategy
to fight the disease.
Dengue is an infectious tropical disease difficult to prevent and manage. Researchers agree
that the development of a vaccine for dengue is a question of high priority. In the present study
we have shown how a vaccine results in reducing morbidity and, simultaneously, in a reduction of
the budget related with the disease. As future work we intend to study the interaction of a dengue
vaccine with other kinds of controls already investigated in the literature, such as insecticide and
educational campaigns [13, 27]. It would be also interesting to investigate what happens if the
final size of the epidemic is included in the objective functional.
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